Glioma - Epidemiology Forecast - 2032

Key Highlights

• Gliomas are extremely diffuse, infiltrative tumors that impact the surrounding brain tissue. According to the American Association of Neurological Surgeons (AANS), gliomas constitute 78% of malignant brain tumors in adults, making them the most common type of brain tumor.
• Glioblastoma (GBM), a Grade IV tumor, represents 15-17% of all primary brain tumors and is the most frequent (50-75%) of gliomas. As per the report submitted by Translational Research Strategy Subcommittee GBM working group, GBM is the most common type of primary malignant brain tumor in the United States, with approximately 13,000 individuals diagnosed annually.
• According to the publisher's analysis, the total incident cases of glioma in the 7MM comprised ~47,000 cases in 2022, which is expected to rise during the forecast period.
• In terms of age-specific stratification, low grade glioma is more prevalent among children and young adults whereas high grade is more prevalent among older adults.
• Recurrence in high grade glioma is almost inevitable occuring in 90-100% of the patients.
• According to reported literature and primary market research findings, gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. IDH1 and IDH2 are the most commonly mutated genes in low-grade glioma, with mutations estimated to occur in >70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma and nonpilocytic pediatric low-grade glioma.

This “Glioma - Epidemiology Forecast - 2032 report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032
Glioma Understanding and Diagnostic Algorithm

Glioma Overview

Glioma is the most common central nervous system (CNS) neoplasm originating from glial cells. They are very diffusely infiltrative tumors that affect the surrounding brain tissue. Three common types of gliomas are classified based on phenotypic cell characteristics: Astrocytomas, ependymomas, and oligodendrogliomas. Gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. Gliomas are further classified into Grades I-IV. Glioblastoma (GBM Grade IV) is the most malignant type, while pilocytic astrocytomas (Grade I) are the least malignant brain tumors among these Grades I-IV. GBMs are further classified into primary and secondary GBMs. Primary GBM occurs de novo without evidence of a less malignant precursor, while secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioma Diagnosis

The diagnosis of glioma includes neurological exams (this exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes, and the ability to think and remember), angiograms, magnetic resonance imaging (MRI) and computerized tomography (CT), surgical biopsy and others. The patient's journey typically starts with symptoms like seizures, unusual headaches, mood and sensory disturbances, and difficulties in walking. The patient underwent a complete physical examination following an initial visit with a general practitioner. The results revealed a few alarming findings related to a brain tumor; the patient was referred to a neuro-oncologist. Further, a neuro-oncologist will immediately recommend an MRI, given that it is the most prominent imaging method, gives good brain images, and aids in the accurate differential diagnosis of brain cancers. A biopsy is carried out to determine the disease's stage if the MRI scans show a glioma. Moreover, molecular examination of biomarkers may be applied to evaluate the type and grade. Once the glioma grade is determined, the patient receives appropriate treatment.

Further details related to diagnosis are provided in the report.

Glioma Epidemiology

The epidemiology forecast model of glioma for the 7MM is based on the analysis of the incident cases of glioma obtained from the overall cases of brain and CNS tumors. The glioma pool is further segmented by grade, age, and type.

As the market is derived using a patient-based model, the glioma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of glioma, grade-specific cases of glioma, age-specific cases of glioma, and type-specific cases of glioma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In 2022, there were approximately 19,000 incident cases of glioma in the United States, contributing to the largest patient pool among the total incident cases of glioma.
• Germany recorded the highest number of glioma cases, i.e., ~25%, among the EU4 countries and the UK, followed by France, while Spain had the fewest cases in 2022.
• Of all the grades, Grade IV accounted for the highest number of incident cases, followed by Grade II glioma, while Grade I had the least number of cases.
• In the 7MM, approximately 67% of the patient share is attributed to GBM, whereas oligoastrocytic tumors contributed the lowest patient share among all the glioma subtypes in 2022.
• Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential and thereby increasing the diagnosis and treatment rate in the coming years, as challenges exist in distinguishing between primary tumors versus metastases and CNS masses by conventional MRI.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted to understand and validate the patient pool, diagnosis gap, evolution in diagnosis and forecasted trends, and unmet need included Medical/scientific writers, Medical Oncologists, and Professors: MD, Oncologist at Memorial Sloan Kettering Cancer Center, Deputy Director of Miami Cancer Institute, and Others.

This analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of glioma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• Patient stratification based on grade-specific and age-specific cases is an inclusion
• A detailed review of current challenges in establishing diagnosis

Glioma Report Insights

• Glioma Patient Population
• Patient Population of Grade I, II, III and IV
• Country-wise Epidemiology Distribution

Glioma Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Glioma Epidemiology Segmentation

Glioma Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices
• Unmet Needs

Key Questions Answered

Epidemiology insights

• What are the disease risks, burdens, and unmet needs of glioma? What will be the growth opportunities across the 7MM with respect to the patient population of glioma?
• What is the historical and forecasted glioma patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which type of glioma is the largest contributor to the glioma patient pool?
• Which age group contributes more to glioma in the 7MM?
• What factors are affecting the increase in the diagnosis rate of glioma?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the grade specific glioma incidence cases in varying geographies over the coming years.
• Detailed overview on type specific cases of glioma is an inclusion
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, and insights on recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.